1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). This funding opportunity invites investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically GLP-1 or dual GLP-1/GIP-1 receptor agonists, impact cancer risk.
The focus includes reported effects on thyroid, prostate, and other cancer risks. The NOFO also aims to attract scientists from other fields to study incretin mimetic effects on cancer biology.
Get alerted about grants like this
Save a search for “National Cancer Institute (NCI), National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs must justify why their proposed agent(s) are more effective and/or have a more favorable side effect profile. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not specified Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is June 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). This funding opportunity supports the development of biomarkers or clinical outcomes from digital health technology for remote monitoring in clinical trials.
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01, Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). This funding opportunity supports the validation of assays developed from existing NIH R01 projects to accelerate their clinical use. This could include mass spectrometry-based assays for secreted protein biomarkers that have shown promise in earlier research.